Will These Numbers from Pfizer Be Good Enough for You?
Pfizer (NYS: PFE) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will wither -14.6% and EPS will wither -16.1%.
The average estimate for revenue is $14.68 billion. On the bottom line, the average EPS estimate is $0.52.
Last quarter, Pfizer recorded revenue of $15.06 billion. GAAP reported sales were 8.7% lower than the prior-year quarter's $16.49 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.62. GAAP EPS of $0.43 for Q2 were 30% higher than the prior-year quarter's $0.33 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 82.1%, 50 basis points better than the prior-year quarter. Operating margin was 36.4%, 470 basis points better than the prior-year quarter. Net margin was 21.6%, 580 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $59.55 billion. The average EPS estimate is $2.21.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,463 members out of 6,055 rating the stock outperform, and 592 members rating it underperform. Among 1,559 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,460 give Pfizer a green thumbs-up, and 99 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.92.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Pfizer to My Watchlist.
The article Will These Numbers from Pfizer Be Good Enough for You? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.